1 withdrawn. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Coagulopathy: new trials by email Literature Review of Coagulopathy trials Research Report on Coagulopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications Camostat Mesylate, Microcrystalline Cellulose, NF - Coagulopathy, Cardiovascular Complication | Phase 1 / Phase 2 | Withdrawn | Yale University | 2021-11-01 | 2022-05-18 |
COVID-19 (1) · Hemostatic Disorders (1)
Cardiovascular Diseases (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemorrhagic Disorders (1) · Infections (1) · Lung Diseases (1) · Nidovirales Infections (1) · Pneumonia (1) · Pneumonia, Viral (1) · RNA Virus Infections (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1) · Vascular Diseases (1)
camostat (1) · microcrystalline cellulose (1)
Yale University (1)
Arya Mani, MD (1)